HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, X. Articles by Tam, S.-P. Search for Related Content PubMed PubMed Citation Articles by Zhang, X. Articles by Tam, S.-P. Social Bookmarking                      What's this?

Volume 271, Number 43, Issue of October 25, 1996 pp. 27152-27160
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Protein-DNA Interactions at a Drug-responsive Element of the Human Apolipoprotein A-I Gene

(Received for publication, May 2, 1996, and in revised form, July 29, 1996)

From the Department of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada

Previously, we demonstrated that when two human hepatoma cell lines, Hep3B and HepG2, were exposed to gemfibrozil, a hypolipidemic drug, a 2-fold induction in apolipoprotein A-I (apoA-I) mRNA levels resulted. To determine if mRNA stabilization was responsible for the changes in apoA-I mRNA levels, the half-lives for apoA-I mRNA were measured in the presence of actinomycin D with and without gemfibrozil. These experiments revealed no differences in stability. However, nuclear run-off assays indicated that the transcription rate of the apoA-I gene was increased 2-fold in gemfibrozil-treated cells. Transient transfection experiments also indicated that the induction of apoA-I mRNA level in response to gemfibrozil is mediated at the transcriptional level. We have identified two copies of the ``drug-responsive element'' (DRE) in the apoA-I promoter region that may be responsible for the increase in apoA-I transcriptional activity by gemfibrozil. Using gel mobility shift assays with a synthetic DRE oligonucleotide, we have demonstrated that exposure of Hep3B and HepG2 cells to gemfibrozil resulted in strong induction of a protein-DNA complex. The formation of this complex is highly sequence-specific as indicated by the DNA competition experiments. The drug-inducible nuclear proteins bind to the DRE of the human apoA-I gene with an apparent K_d of 4.1 nM. Methylation interference experiments have localized the contact sites of nuclear factors to the DRE region. Southwestern blot analyses have identified two groups of drug-inducible nuclear proteins with molecular masses of approximately 30 and 15 kDa. When a copy of synthetic DRE oligonucleotide was inserted upstream of the thymidine kinase promoter and luciferase reporter construct, a significant 2-fold induction in luciferase activity was observed in the presence of gemfibrozil following transient transfection of two human hepatoma cell lines, HepG2 and Hep3B. However, a plasmid containing one copy of mutated apoA-I-DRE oligomer did not confer responsiveness to gemfibrozil treatment. Furthermore, pGL2 (apoA-I 250 mutant DRE), which carried an internal mutation of the DRE in the human apoA-I proximal promoter region, showed no increase in luciferase activity in response to gemfibrozil. These results implicate protein-DNA interactions at the DRE region in the transcriptional induction of human apoA-I gene expression by gemfibrozil.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. R. Bhavnani, S.-P. Tam, and X. Lu Structure Activity Relationships and Differential Interactions and Functional Activity of Various Equine Estrogens Mediated via Estrogen Receptors (ERs) ER{alpha} and ER{beta} Endocrinology, October 1, 2008; 149(10): 4857 - 4870. [Abstract] [Full Text] [PDF]

				S. C. Smith Jr, R. V. Milani, D. K. Arnett, J. R. Crouse III, M. M. McDermott, P. M Ridker, R. S. Rosenson, K. A. Taubert, and P. W.F. Wilson Atherosclerotic Vascular Disease Conference: Writing Group II: Risk Factors Circulation, June 1, 2004; 109(21): 2613 - 2616. [Full Text] [PDF]

				J. M Ordovas, D. Corella, L A. Cupples, S. Demissie, A. Kelleher, O. Coltell, P. W. Wilson, E. J Schaefer, and K. Tucker Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study Am. J. Clinical Nutrition, January 1, 2002; 75(1): 38 - 46. [Abstract] [Full Text] [PDF]

				B. Gauthier, M. Robb, F. Gaudet, G. S. Ginsburg, and R. McPherson Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl ester transfer protein gene: functional role of the transcription factors SREBP-1a, -2, and YY1. J. Lipid Res., July 1, 1999; 40(7): 1284 - 1293. [Abstract] [Full Text]

				W. S. Mohan, Z.-Q. Chen, X. Zhang, K. Khalili, T. Honjo, R. G. Deeley, and S.-P. Tam Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter: role of gemfibrozil J. Lipid Res., February 1, 1998; 39(2): 255 - 267. [Abstract] [Full Text]

				C. Cuthbert, Z. Wang, X. Zhang, and S.-P. Tam Regulation of Human Apolipoprotein A-I Gene Expression by Gramoxone J. Biol. Chem., June 6, 1997; 272(23): 14954 - 14960. [Abstract] [Full Text] [PDF]